
EULAR recommendations for the management of systemic lupus erythematosus
The highlights of the latest update of the EULAR recommendations for the management of systemic lupus erythematosus (SLE), based on emerging new evidence, are discussed in this podcast.Read the full paper on the ARD website: https://ard.bmj.com/content/78/6/736.
10mins
12 Jul 2019
Rank #1

Patient and doctor discordance may reduce chances of remission in rheumatoid and psoriatic arthritis
Discordance between patient's and physician's evaluation of disease activity may reduce likelihood of remission in rheumatoid arthritis and psoriatic arthritis. Dr Paul Studenic, Austria, is joined by Dr Brigitte Michelsen and Prof Tore Kvien, both from the department of Rheumatology at the Diakonhjemmet Hospital in Oslo, Norway, to discuss their study "Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study".Read the full details on the Annals of the Rheumatic Diseases website (http://ard.bmj.com/content/76/4/708), where you can also find the related Lay Summary (https://goo.gl/JBQbFc).
9mins
31 Jan 2018
Rank #2
Similar Podcasts

Early inflammatory arthritis outcomes: what changed in the new millennium?
A study that compares the 10-year outcome (disease activity, disability, mortality) of two cohorts of patients with inflammatory polyarthritis recruited 10 years apart is discussed in this podcast. The results from the UK’s Norfolk Arthritis Register are shared by two of its co-authors from the Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, School of Biological Sciences, Manchester Academic Health Science Centre: James Gwinnutt and Suzanne Verstappen (NIHR Manchester Biomedical Research Centre) in conversation with the social media advisor for ARD Meghna Jani.Read the full paper on the Annals of the Rheumatic Diseases website: https://ard.bmj.com/content/77/6/848.
9mins
10 Jul 2018
Rank #3

Lupus and Hughes syndrome: EULAR recommendations for women's health and family planning
What are the recommendations of The European League Against Rheumatism (EULAR) for women's health and family planning after a diagnosis of lupus and/or antiphospholipid syndrome, also known as Hughes syndrome?Alessia Alunno (Rheumatology Unit, University of Perugia, Italy) talks to Laura Andreoli (Rheumatology and Clinical Immunology Unit, University of Brescia, Italy) about her paper recently published by ARD (ard.bmj.com)."EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome" is available here: http://ard.bmj.com/content/76/3/476.
9mins
20 Apr 2017
Rank #4
Most Popular Podcasts

Capture Hi-C reveals novel drug targets in rheumatic diseases
The paper discussed in this podcast provides an approach, using Capture Hi-C data, to link genetic associations to potential causal genes and assess the potential of drug repurposing in three rheumatic diseases. This has the potential to identify genes which are functionally relevant and the target of existing therapies, which could provide new ways to treat patients, enhancing their quality of life and reducing the economic impact on healthcare providers. Read the full paper on the ARD website: https://ard.bmj.com/content/78/8/1127.
14mins
22 Aug 2019
Rank #5

TULIP 1 - highlights from the ACR meeting
TULIP 1: A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus ErythematosusIn this first phase 3 trial, the primary endpoint, SRI(4), was not achieved, but numeric improvements achieving thresholds associated with clinical benefit were observed for BICLA, oral corticosteroid tapering and other organ-specific endpoints.
4mins
10 Dec 2019
Rank #6

Highlights from ACR: guselkumab, ixekizumab and secukinumab in SpA
Atul Deodhar, from the Oregon Health & Science University, provides an overview of recent clinical trial results in the area of seronegative Spondylarthritis. He presented the 24-week data of Guselkumab in active psoriatic arthritis patients in the DISCOVER-1 study and compared the phase 3 trials in non-radiographic SpA patients on Ixekizumab (COAST-X) and Secukinumab (PREVENT) with up to 52 week data available.
14mins
23 Jan 2020
Rank #7

Three tips to get your manuscript published by ARD
Find out how to increase your chances of a successful submission in this very short podcast with Annals of the Rheumatic Diseases’s Associate Editor Francis Berenbaum. He is interviewed by the Social Media Advisor of the journal, Christophe Richez.Read more information for authors on the ARD website: https://ard.bmj.com/pages/authors/.Submit your manuscript here: https://mc.manuscriptcentral.com/ard.
4mins
29 Aug 2018
Rank #8

TULIP 2: Efficacy and Safety of Anifrolumab in Patients
TULIP 2: Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial.In this second phase 3 trial, the primary endpoint, BICLA, was achieved, and anifrolumab was superior to placebo for multiple secondary efficacy endpoints, including SRI(4), skin disease, and oral corticosteroid tapering.
3mins
23 Dec 2019
Rank #9

Similar performance of Humira and BI695501 biosimilar in active rheumatoid arthritis
The switch from Humira to BI 695501 had no impact on efficacy, safety and immunogenicity in patients with moderately to severely active rheumatoid arthritis, according to a study recently published by ARD and discussed in this short podcast.Professor Stanley Cohen (Metroplex Clinical Research Center, Dallas, Texas, USA) tells ARD’s social media advisor Elena Nikiphorou (clinical researcher at King’s College London, UK) how the conclusions should have an important economic impact, particularly in less favoured clinical settings in the world.Read the full paper on the Annals of the Rheumatic Diseases website: http://dx.doi.org/10.1136/annrheumdis-2017-212245.
15mins
28 Mar 2018
Rank #10